GLPGF Galapagos NV (PK)

  * Identification and validation of novel targets in scleroderma
  * Will leverage Galapagos' SilenceSelect(®) platform and unique human skin
    models


Galapagos  NV (Euronext: GLPG) announced
today  that its subsidiary BioFocus signed a 3-year collaboration agreement with
Biogen  Idec focused  on the  identification and  validation of novel targets in
scleroderma.

Galapagos'  service division BioFocus will use its SilenceSelect(®) platform and
unique  human skin models  to deliver new  assays and identify disease-modifying
targets  in  scleroderma  to  Biogen  Idec.   Under  the terms of the agreement,
BioFocus  will receive an upfront payment, FTE  funding, and will be eligible to
receive  success payments  for target  discovery milestones  to be  delivered by
BioFocus and development milestones achieved by Biogen Idec.  The total value of
this collaboration to BioFocus could reach $31 million.

"We  believe Galapagos has  unique expertise with  relevant human primary cells,
positioning  them  well  to  find  new  targets  for disease-modifying therapies
against  scleroderma," said  Jo Viney,  vice president  of discovery sciences at
Biogen Idec.

"We  welcome Biogen  Idec to  our client  base and  look forward to applying our
versatile  target discovery  engine to  yet another  new disease area with unmet
medical need," added David Smith, CEO Galapagos Services.

Scleroderma  is an autoimmune  disease characterized by  hardening of the skin.
Patients with diffuse scleroderma also experience hardening of the organs, which
can  be particularly disabling and also  fatal.  Scleroderma is found worldwide,
affecting 1 in 1000 in the United States, with women four times more likely than
men  to  develop  the  disease.   The  root  causes  of the disease are not well
understood, and there are no disease-modifying treatments.

About BioFocus
BioFocus provides integrated drug discovery that delivers pre-clinical drug
candidates in all therapeutic areas with strong capabilities in
neurodegenerative diseases, inflammatory diseases and rare and neglected
diseases.  BioFocus has advanced and comprehensive drug discovery capabilities
that are applied to client projects to deliver targets, hits, leads and pre-
clinical candidates.  The company employs over 150 scientists at its research
centres in the UK and the Netherlands.  For more information, visit us at
Twitter, LinkedIn, Google+ and at www.biofocus.com.

About Galapagos
Galapagos  (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with  a large pipeline of  five Phase 2 (two led  by GSK), one Phase 1, six pre-
clinical,  and  20 discovery  small-molecule  and  antibody  programs  in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
AbbVie  and Galapagos signed an agreement  in CF where they work collaboratively
to  develop and commercialize oral drugs that  address two mutations in the CFTR
gene,  the G551D and F508del mutation.  In the field of inflammation, AbbVie and
Galapagos   signed   a  worldwide  license  agreement  whereby  AbbVie  will  be
responsible  for  further  development  and  commercialization of GLPG0634 after
Phase  2B.  GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
treatment  of rheumatoid arthritis and  potentially other inflammatory diseases,
currently  in  Phase  2B studies  in  RA  and  about to enter Phase 2 studies in
Crohn's  disease.  Galapagos has another selective  JAK1 inhibitor in Phase 2 in
lupus   and   psoriasis,   GSK2586184   (formerly   GLPG0778,   in-licensed   by
GlaxoSmithKline  in  2012).  GLPG0974  is  the  first  inhibitor  of  FFA2 to be
evaluated  clinically for the treatment  of IBD; this program  is currently in a
Proof-of-Concept  Phase  2 study.   GLPG1205  is  a first-in-class molecule that
targets  inflammatory disorders  and is  currently in  a First-in-Human Phase 1
study.
The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta and
Fidelta,  has around  800 employees and  operates facilities  in five countries,
with   global  headquarters  in  Mechelen,  Belgium.   Further  information  at:
www.glpg.com

Contact

Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com

This   release   may  contain  forward-looking  statements,  including,  without
limitation,   statements   containing   the   words  "believes,"  "anticipates,"
"expects,"  "intends,"  "plans,"  "seeks,"  "estimates," "may," "will," "could,"
"stands  to," and  "continues," as  well as  similar expressions.  Such forward-
looking  statements may involve known and unknown risks, uncertainties and other
factors  which might cause the  actual results, financial condition, performance
or  achievements of Galapagos,  or industry results,  to be materially different
from  any  historic  or  future  results,  financial  conditions, performance or
achievements  expressed or  implied by  such forward-looking  statements.  Given
these  uncertainties, the reader is  advised not to place  any undue reliance on
such forward-looking statements.  These forward-looking statements speak only as
of  the date of publication of this document.  Galapagos expressly disclaims any
obligation  to update  any such  forward-looking statements  in this document to
reflect  any change  in its  expectations with  regard thereto  or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.

[HUG#1742206]

Galapagos NV (PK) (USOTC:GLPGF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Galapagos NV (PK) (USOTC:GLPGF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024